2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

CAR-T in Autoimmune Diseases

Moffitt Cancer Center

A. Mirza

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

Treating Patients With DLBCL Who Are Not Eligible for CAR-T Therapy

Remy Dulery

Sequencing Cellular Therapy and Bispecific Antibodies in DLBCL

Megan Melody

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

ASH 2024 Insights: Outcomes With Bispecific Antibodies Post-CAR T-Ce…

2024 ASH Annual Meeting Insights Hub

M. Melody

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Updates on Approved CAR-Ts for Lymphomas

Moffitt Cancer Center

J. Chavez

2025 Updates in DLBCL

Total Health

F. Hagemeister

ASH 2024 Insights: Timing of CAR-T Failure as a Predictor of Outcome…

2024 ASH Annual Meeting Insights Hub

E. Shumilov

Infectious Disease Perspective of CAR T-Cell Therapy

Moffitt Cancer Center

A. Baluch

Managing R/R LBCL Patients Treated With Pola-R-CHP in 1L and Are CAR…

University of Colorado Cancer Center

M. Kamdar

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

ASH 2024 Insights: Odronextamab in R/R DLBCL Post-CAR T-Cell Progres…

2024 ASH Annual Meeting Insights Hub

M. Matasar

ASH 2024 Treatment Updates in Lymphoma: Practice Changing and Promis…

UChicago Medicine

A. Rojek

DLBCL: Treatment Options for Transplant-Ineligible Patients

Amit Mehta

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Updates in CAR-T Therapy for Aggressive Lymphomas

Vanderbilt University Medical Center (VUMC)

B. Dholaria